UCB (OTCMKTS:UCBJF) Shares Gap Down – What’s Next?

UCB SA (OTCMKTS:UCBJF)’s share price gapped down before the market opened on Tuesday. The stock had previously closed at $305.59, but opened at $292.20. UCB shares last traded at $292.20, with a volume of 51 shares traded.

Analyst Upgrades and Downgrades

UCBJF has been the topic of several recent analyst reports. Piper Sandler restated a “neutral” rating on shares of UCB in a research note on Wednesday, July 22nd. Stephens reaffirmed an “overweight” rating on shares of UCB in a report on Wednesday, October 21st. Finally, Jefferies Financial Group upgraded shares of UCB to a “hold” rating in a research note on Monday, August 3rd. Five investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy”.

UCB Price Performance

The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33. The firm has a fifty day moving average price of $251.97 and a 200-day moving average price of $285.64.

UCB Company Profile

UCB is a Belgium-based biopharmaceutical company focused on discovering, developing and commercializing medicines for people living with severe diseases. Its primary therapeutic areas are neurology and immunology, with research activities spanning conditions such as epilepsy, myasthenia gravis, Parkinson’s disease, psoriasis, psoriatic arthritis, axial spondyloarthritis and other immune-mediated disorders.

The company’s medicines include Bimzelx (bimekizumab), an immunology treatment; Cimzia (certolizumab pegol), used for several inflammatory conditions; and a portfolio of neurological therapies that includes Briviact (brivaracetam), Keppra (levetiracetam), Fintepla (fenfluramine) and Nayzilam (midazolam).